Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Genetic Basis of Acquired Heart Disease in Africa

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02124109
Recruitment Status : Completed
First Posted : April 28, 2014
Last Update Posted : March 12, 2019
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Human Genome Research Institute (NHGRI) )

Brief Summary:

Background:

- An acquired heart disease is one that a person gets after they are born. Two of these are rheumatic heart disease (RHD) and endomyocardial fibrosis (EMF). They are found more commonly in people who live in Africa than in other places in the world. Researchers want to learn more about these diseases. They especially want to know what role genes and other factors play in them.

Objective:

- To identify genetic risk factors for RHD and EMF in sub-Saharan Africa.

Eligibility:

  • Children and adults with RHD or EMF.
  • Healthy volunteers over age 10.

Design:

  • Participants will come from existing study groups in Uganda and Nigeria.
  • Participants may be required to provide a sample of their DNA. They will do this with either a blood or saliva sample or a swab of the mouth.
  • Collected samples will be labeled with a code and sent to a lab in the United States for analysis. Remaining portions of participants samples will be stored for an unlimited period of time. They may be used in future studies.
  • Some genetic and health information from participants might be placed into one or more scientific databases.
  • Participant names and identifying information will be kept private. But there is a small chance someone could trace them from their genetic information.

Condition or disease
Rheumatic Heart Disease Rheumatic Fever Endomyocardial Fibrosis Acquired Heart Disease

Detailed Description:
Recent advances in genomic techniques are making possible a new wave of genetic discovery in many complex diseases. However, the genetic risk factors for two forms of acquired heart disease that are particularly common in Africa - rheumatic heart disease (RHD) and endomyocardial fibrosis (EMF) remains unknown. In this application, we propose to evaluate genetic risk factors for rheumatic heart disease (RHD) and endomyocardial fibrosis (EMF). A number of factors should facilitate the identification of genetic risk variants underlying the two conditions. First, both forms of acquired heart disease are endemic to sub-Saharan Africa (SSA). Second, affected patients and those who do not develop the conditions share a common environment. Finally, the availability of high density SNP arrays to capture common and rare variation makes the characterization of genomic variation better than ever. Patients will be enrolled at the Uganda Heart Institute in Kampala, Uganda, and at the College of Medicine, University of Lagos, Nigeria, with the potential to include other African sites. Genomic studies will be done at the NIH.

Layout table for study information
Study Type : Observational
Actual Enrollment : 736 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: The Genetic Basis of Acquired Heart Disease in Africa
Actual Study Start Date : April 3, 2014
Actual Primary Completion Date : March 8, 2019
Actual Study Completion Date : March 8, 2019


Group/Cohort
rheumatic heart disease
Patients with rheumatic heart disease
Control
Control group



Primary Outcome Measures :
  1. Extension of study [ Time Frame: ongoing ]
    Extend our previous epidemiological studies of RHD in Ugandan schoolchildren (Beaton et al 2012) by conducting a similar study ofRHD in Nigerian children



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 100 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients with rheumatic heart disease@@@
Criteria
  • INCLUSION CRITERIA:
  • Rheumatic Heart Disease:

Patients with a definite diagnosis of rheumatic heart disease based on the 2006 World Health Organization/National Institutes of Health Joint Criteria (http://www.niaid.nih.gov/topics/strepThroat/Documents/groupasequelae.pdf) controls who do not meet this criteria. The diagnosis will be made by a cardiologist on our team. The method of screening and recruitment will be specific to each of our two sites: Uganda Heart Institute and University of Lagos, Nigeria.

-Uganda Heart Institute:

--recruitment will be conducted from an existing cohort of patients initially recruited by members of our team from 21 randomly selected

schools in Uganda. Participants meeting the criteria noted above for RHD will be considered cases and those who do not will be considered controls. Additionally, parents will be invited to participate as controls. For controls, only children over age 10 will be considered as this increases the likelihood of exposure

to S. pyogenes. The initial study was approved by the institutional review boards of the Children s National Medical Center (Washington,D.C.), Makerere University (Kampala, Uganda), and the

Ugandan Ministries of Health and Education

-University of Lagos:

--This program will be modeled after the Uganda program. Participants will be screened for RHD at the College of Medicine or at randomly selected schools. Participants meeting criteria for RHD will be consented as cases and those negative for RHD will be consented as controls. Additionally, parents will be invited to

participate as controls. For controls, only children over age 10 will be considered as this increases the likelihood of exposure to S. pyogenes

-Endomyocardial Fibrosis (EMF):

  • Cases: the study will include patients with a diagnosis of EMF based on echocardiography, history, and physical exam performed by cardiologist;on our team Over 50 patients have been identified at the Uganda Heart Institute with EMF and will be contacted for study participation; additionally, newly diagnosed patients at the Uganda Heart Institute will be offered participation.
  • Controls: Geographic and age matched controls will be used for association study. Controls will be disease free, based on above criteria. We will exclude controls less than 15 years of age based on disease peak around age 10. Controls will be selected from those being screening for RHD

EXCLUSION CRITERIA:

-Anyone unwilling to provide informed consent (for themselves as adults, or on behalf of their children as minors) or assent.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02124109


Locations
Layout table for location information
Nigeria
University of Lagos
Lagos, Nigeria
Uganda
Mulago Hospital
Kampala, Uganda
Sponsors and Collaborators
National Human Genome Research Institute (NHGRI)
Investigators
Layout table for investigator information
Principal Investigator: Maximilian Muenke, M.D. National Human Genome Research Institute (NHGRI)

Publications:
Layout table for additonal information
Responsible Party: National Human Genome Research Institute (NHGRI)
ClinicalTrials.gov Identifier: NCT02124109     History of Changes
Other Study ID Numbers: 999914098
14-HG-N098
First Posted: April 28, 2014    Key Record Dates
Last Update Posted: March 12, 2019
Last Verified: February 14, 2019

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Human Genome Research Institute (NHGRI) ):
Rheumatic Heart Disease

Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Rheumatic Diseases
Rheumatic Heart Disease
Rheumatic Fever
Endomyocardial Fibrosis
Cardiovascular Diseases
Musculoskeletal Diseases
Connective Tissue Diseases
Streptococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Arthritis
Joint Diseases
Cardiomyopathies